pharmaphorum September 22, 2025
MSD’s cancer immunotherapy Keytruda will soon be available as a subcutaneous injection that does away with the need to visit an infusion clinic.
Keytruda Qlex (pembrolizumab and berahyaluronidase alfa) still needs to be administered by a healthcare professional, but requires just a couple of minutes to deliver, rather than a 30-minute intravenous infusion. It is administered every three or six weeks, similar to the IV version and, according to MSD, it can cut the ‘chair and treatment’ time for patients in half.
The FDA has cleared the new version for across most of the solid tumour indications already granted for Keytruda, which is MSD’s biggest-selling drug – bringing in more than $15 billion in the first half of this year...
Today's Sponsors
Today's Sponsor